RayKnowChina Research Map
Shortlist0

Wuhan University

武汉大学

WuhanUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
1.1%Leads about 1 in 88 of China's research papers on NPC

Led 27 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
27
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 002025
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueImaging & AI

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Renmin Hospital of Wuhan University13
  2. Zhongnan Hospital of Wuhan University11
  3. Central Hospital, Wuhan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Fluoroscopy-Guided Balloon Dilation for Severe Nasopharyngeal Stenosis Resulting from Radiotherapy for Nasopharyngeal Carcinoma.2024Cardiovascular and interventional radiology
  2. Predicting prognosis of nasopharyngeal carcinoma based on deep learning: peritumoral region should be valued.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  3. Deep Learning for Predicting Distant Metastasis in Patients with Nasopharyngeal Carcinoma Based on Pre-Radiotherapy Magnetic Resonance Imaging.2023Combinatorial chemistry & high throughput screeningFree full text
  4. Deep learning for locally advanced nasopharyngeal carcinoma prognostication based on pre- and post-treatment MRI.2022Computer methods and programs in biomedicine
  5. Homing Effect Directed Cuprous Delivery Activates Cuproptosis Against Nasopharyngeal Carcinoma and Metastasis.2026Small (Weinheim an der Bergstrasse, Germany)
Trials on ClinicalTrials.gov6
  1. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  2. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
  3. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Study sitePhase 3Start 2022-04
  4. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid TumorRecruitingNCT05194982Study sitePhase 1Start 2021-11
  5. Immune Score Based Radiomics in Nasopharyngeal CarcinomaRecruitingNCT05126160Study siteStart 2021-11
  6. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Study sitePhase 3Start 2020-03

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.5%Leads under 1 in 100 of China's research papers on ESCC

Led 15 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
2
Research papers it led
15
Trials it led
3
Share of China's trials
0.5%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 222025
ThemesRadiotherapyImmunotherapyMolecular markers & genomics

Hospitals counted here

  1. Renmin Hospital of Wuhan University12
  2. Zhongnan Hospital of Wuhan University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.2022JAMA network openFree full text
  2. Efficacy and Safety of Second-Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.2025Thoracic cancerFree full text
  3. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  4. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  5. Porphyromonas gingivalis extracellular vesicles promotes tumor metastasis in esophageal squamous cell carcinoma by inducing PRKACB/JNK/ NFATC2 axis.2025Journal of nanobiotechnologyFree full text
Trials on ClinicalTrials.gov5
  1. A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05919030Lead sponsorPhase 3Start 2023-07
  2. Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell CarcinomaRecruitingNCT05894369Lead sponsorStart 2023-05
  3. The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal CancerCompletedNCT04212598Lead sponsorPhase 2Start 2020-08
  4. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  5. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.3%Leads about 1 in 76 of China's research papers on HCC

Led 194 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
0
Research papers it led
194
Trials it led
8
Share of China's trials
0.5%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 222025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Zhongnan Hospital of Wuhan University97
  2. Renmin Hospital of Wuhan University84
  3. Renmin Hospital Counted in the group total2
  4. Wuhan University Renmin Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A genome-wide siRNA screen identifies previously unknown proviral and antiviral host factors in HBV infection.2026Journal of hepatology
  2. Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.2023Journal of hepatology
  3. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.2023Cancer communications (London, England)Free full text
  4. Clinical performance evaluation of a plasma dual-target methylation test for the detection of primary liver cancer: a multicenter study.2025Clinical epigeneticsFree full text
  5. Splenic volume as a predictor of survival in cancer patients treated with immune checkpoint inhibitors.2025Frontiers in immunologyFree full text
Trials on ClinicalTrials.gov6
  1. Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular CarcinomaStatus unknownNCT05575622Lead sponsorStart 2023-01
  2. Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT05282433Lead sponsorPhase 2Start 2022-04
  3. Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune MicroenvironmentStatus unknownNCT05677724Lead sponsorStart 2022-07
  4. Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic MalignanciesStatus unknownNCT05240690Lead sponsorPhase 1Start 2022-02
  5. Clinical Study of MAK Immune Cells in the Treatment of PHCStatus unknownNCT05242757Lead sponsorN/AStart 2021-01
  6. Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver CancerStatus unknownNCT04688606Lead sponsorStart 2020-01

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.1%Leads about 1 in 94 of China's research papers on Stomach cancer

Led 104 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
3
Research papers it led
104
Trials it led
12
Share of China's trials
0.8%
Share of the world's papers
0.5%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 112025
ThemesEarly detection & endoscopyImaging & AIPeritoneal spread & advanced disease

Hospitals counted here

  1. Renmin Hospital of Wuhan University73
  2. Zhongnan Hospital of Wuhan University29
  3. Wuhan University Renmin Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effect of a deep learning-based system on the miss rate of gastric neoplasms during upper gastrointestinal endoscopy: a single-centre, tandem, randomised controlled trial.2021The lancet. Gastroenterology & hepatologyRCT
  2. Evaluation of the effects of an artificial intelligence system on endoscopy quality and preliminary testing of its performance in detecting early gastric cancer: a randomized controlled trial.2021EndoscopyRCT
  3. Artificial intelligence assistance narrows the experience gap in endoscopic reporting of gastric lesions: a prospective clinical trial.2026Surgical endoscopyFree full text
  4. Efficacy of endoscopic therapy in patients with T1b gastric cancer and construction of a prognostic prediction model: a retrospective cohort study and multicenter validation study.2026Surgical endoscopyFree full text
  5. SIRT1 Expression in Human Gastrointestinal Tumors and Its Clinical Significance.2025Cancer medicineFree full text
Trials on ClinicalTrials.gov6
  1. A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric CancerNot yet recruitingNCT06464601Lead sponsorStart 2025-04
  2. A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant TumorsNot yet recruitingNCT06496919Lead sponsorStart 2024-08
  3. Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant DiseaseRecruitingNCT03972956Lead sponsorStart 2020-12
  4. Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)RecruitingNCT07401199Study siteStart 2026-02
  5. First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GCCompletedNCT06238752Lead sponsorPhase 2Start 2021-03
  6. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric CancerStatus unknownNCT04345770Lead sponsorPhase 2Start 2020-04

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
2.7%Leads about 1 in 38 of China's research papers on Retinoblastoma ▼ from 3.6%

Led 8 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 0020242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Renmin Hospital of Wuhan University4
  2. Zhongnan Hospital of Wuhan University2
  3. Wuhan University Renmin Hospital1
  4. Aier Eye Hospital, Wuhan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
2.3%Leads about 1 in 43 of China's research papers on Osteosarcoma ▲ from 1.6%

Led 52 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
52
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Renmin Hospital of Wuhan University30
  2. Zhongnan Hospital of Wuhan University19
  3. Wuhan University Renmin Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.6%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour

Led 3 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Renmin Hospital of Wuhan University2
  2. Zhongnan Hospital of Wuhan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.5%Leads about 1 in 67 of China's research papers on Neuroblastoma ▲ from 1.0%

Led 17 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 1120242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Renmin Hospital of Wuhan University10
  2. Zhongnan Hospital of Wuhan University6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Wuhan University Renmin Hospital1
  2. Zhongnan Hospital of Wuhan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.7%Leads under 1 in 100 of China's research papers on Myeloma

Led 12 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
3
Research papers it led
12
Trials it led
6
Share of China's trials
1.2%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 2220242025: 002025
ThemesDiagnosis, MRD & riskDrug combinationsKidney & bone complications

Hospitals counted here

  1. Zhongnan Hospital of Wuhan University12

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Clinical and immunological characteristics of high-risk double-hit multiple myeloma.2024BMC cancerFree full text
  2. Chemotherapy plus therapeutic plasmapheresis with 4% human albumin solution in multiple myeloma patients with acute kidney injury: a prospective, open-label, proof-of-concept study.2024Renal failureFree full text
  3. Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion.2023Journal of cancer research and clinical oncologyFree full text
  4. Extracellular Volume Fraction Based on Cardiac Magnetic Resonance T1 Mapping: An Effective Way to Evaluate Cardiac Injury Caused by Cardiac Amyloidosis in Patients with Multiple Myeloma.2022Journal of immunology researchFree full text
  5. Analysis of Risk Factors of Coagulation Dysfunction and Hemorrhage in Newly Diagnosed Hyperleukocytic Acute Myeloma Leukemia.2022Contrast media & molecular imagingFree full text
Trials on ClinicalTrials.gov6
  1. Randomised Controlled Trial of Artificial Intelligence-assisted Health EducationRecruitingNCT07305337Lead sponsorN/AStart 2025-06
  2. Helical Tomotherapy in Multiple MyelomaRecruitingNCT05970198Lead sponsorN/AStart 2023-06
  3. AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH AbnormalitiesEnrolling by invitationNCT07410403Lead sponsorStart 2018-08
  4. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  5. A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple MyelomaNot yet recruitingNCT06799676Study sitePhase 1/Phase 2Start 2025-02
  6. Double Filtration Plasmapheresis Combined With ChemotherapyStatus unknownNCT04836871Lead sponsorPhase 1Start 2021-05

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.7%Leads under 1 in 100 of China's research papers on Aplastic anaemia New since 2021

Led 3 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Zhongnan Hospital of Wuhan University2
  2. Renmin Hospital of Wuhan University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fanconi anaemia

范可尼贫血
2.9%Leads about 1 in 34 of China's research papers on Fanconi anaemia New since 2021

Led 2 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Zhongnan Hospital of Wuhan University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
0.2%Leads under 1 in 100 of China's research papers on Myasthenia gravis ▼ from 1.3%

Led 1 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.04%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025
ThemesEye-only (ocular) myasthenia

Hospitals counted here

  1. Aier Eye Hospital, Wuhan University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
3.6%Leads about 1 in 27 of China's research papers on Moyamoya ▼ from 9.2%

Led 13 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025
ThemesRevascularisation surgeryImaging & blood flowChildren

Hospitals counted here

  1. Zhongnan Hospital of Wuhan University13

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
1.1%Leads about 1 in 88 of China's research papers on Anti-NMDA receptor encephalitis New since 2021

Led 3 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025

Hospitals counted here

  1. Zhongnan Hospital of Wuhan University2
  2. Renmin Hospital of Wuhan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.7%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis

Led 7 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Zhongnan Hospital of Wuhan University6
  2. Renmin Hospital of Wuhan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.9%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis ▲ from 0.3%

Led 7 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Renmin Hospital of Wuhan University3
  2. Zhongnan Hospital of Wuhan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
1.6%Leads about 1 in 61 of China's research papers on Behçet disease ▲ from 0.7%

Led 4 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Zhongnan Hospital of Wuhan University2
  2. Renmin Hospital of Wuhan University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.5%Leads under 1 in 100 of China's research papers on IgA nephropathy New since 2021

Led 4 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Renmin Hospital of Wuhan University2
  2. Wuhan University Hospital1
  3. Zhongnan Hospital of Wuhan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
3.4%Leads about 1 in 29 of China's research papers on Familial adenomatous polyposis New since 2021

Led 2 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Renmin Hospital of Wuhan University2
  2. Zhongnan Hospital of Wuhan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Leber hereditary optic neuropathy

Leber 遗传性视神经病变
3.9%Leads about 1 in 26 of China's research papers on Leber hereditary optic neuropathy New since 2021

Led 2 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (21.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Renmin Hospital of Wuhan University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov